Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DTwP-HepB-IPV-Hib vaccine - Serum Institute of India

Next Previous
Drug Profile

DTwP-HepB-IPV-Hib vaccine - Serum Institute of India

Alternative Names: HEXASIIL

Latest Information Update: 26 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Serum Institute of India
  • Class Bacterial toxins; Bacterial vaccines; Conjugate vaccines; Haemophilus vaccines; Hepatitis B vaccines; Influenza virus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 17 Mar 2025 PATH plans a phase II trial for Malaria (Prevention) in Burkina Faso (IM) (NCT06879327)
  • 06 May 2024 Serum Institute of India initiates a phase III trial for Diphtheria, Haemophilus-infections, Hepatitis-B, Pertussis, Poliomyelitis, and Tetanus (In infants, Prevention) in India (IM, Injection) (NCT06413121)
  • 19 Sep 2022 Serum Institute of India completes enrollment in a phase II/III trial in Diphtheria, Hepatitis B, Haemophilus infections, Pertussis, Poliomyelitis and Tetanus (In infants, Prevention) in India (IM) (CTRI/2019/11/022052)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top